Therapeutic plasma exchange (TPE) is increasingly used throughout the world. Although the procedure itself is fairly standardized, it is yet unknown how the underlying disease entities influence the key coordinates of the treatment.
Retrospective chart review. The treatment indications were clustered into four categories. Data are presented as median and interquartile (25–75%) range [IQR].
Within 1 year, 912 TPE treatments were performed in 185 patients (90 female, 48.6%). The distribution of the treatment numbers to the pre-specified disease categories were as follows: transplantation (35.7%), neurology (31.9%), vasculitis and immunological disease (17.3%), and others including thrombotic microangiopathy (8.1%), critical care related diseases (5.4%), hematology [multiple myeloma] (1.1%), and endocrine disorders (0.5%). The calculated plasma volume was significantly higher in patients with vasculitis and immunological diseases (3984 [3433–4439] ml) as compared to patients treated for transplant related indications (3194 [2545–3658] ml; p = 0.0003) and neurological diseases (3058 [2533–3359] ml; p < 0.0001). This was mainly due to the differences in the hematocrit which was 30.5 [27.0–33.6] % in the vasculitis/immunological disease patients and 40.2 [37.5–42.9] % in the neurological patients; p < 0.0001. Interestingly, treatment time using a membrane based technology was significantly longer than TPE using a centrifugal device 135.0 [125.0–140.0] min vs. 120.0 [112.5–135.0] min. Furthermore, the relative exchanged plasma volume was significantly lower in the treatment of vasculitis and immunological diseases as compared to treatments of transplant related indications and neurological diseases.
Patients with low hematocrit and high body weight do not receive the minimum recommended dose of exchange volume. Centrifugal TPE allowed faster plasma exchange than membrane TPE.
Abel JL, Rowntree LG, Turner BB. Plasma removal with return of corpuscles (plasmaphaeresis). J Pharmacol Exp Ther. 1914;5:625–41.
Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the use of therapeutic Apheresis in clinical practice-evidence-based approach from the writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher. 2016;31:149–62. PubMed
Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, Nurnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, Brunkhorst R. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-Toxin-Producing E. Coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant. 2012;27:3807–15. CrossRefPubMed
Eden G, Gradaus F, Brown K, Gauert I, Sass C, Kielstein JT. Therapeutic plasma exchange for the treatment of hypertriglyceridemia-induced pancreatitis: a case report. Med Klin Intensivmed Notfmed. 2017;112(5):471–4.
Walsh M, Merkel PA, Peh CA, Szpirt W, Guillevin L, Pusey CD, De ZJ, Ives N, Clark WF, Quillen K, Winters JL, Wheatley K, Jayne D. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013;14:73. CrossRefPubMedPubMedCentral
MJ W, Shu KH, Cheng CH, Lian JD. Complications of membrane-filtration plasma exchange. Zhonghua Yi Xue Za Zhi (Taipei). 1997;60:147–54.
- Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis
Julius J. Schmidt
Jan T. Kielstein
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II